Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against Pseudomonas aeruginosa by Inhibiting Drug Efflux.

Wei X, Zhou D, Xu C, Chen P, Chen S, Cheng Z, Jin Y, Jin S, Wu W

Antibiotics (Basel, Switzerland)26 Aug 2024Cited by 8 (Europe PMC)

PMID39334985PMCIDPMC11429200DOI10.3390/antibiotics13090810PepBankPUB-39334985

Summary

Pseudomonas aeruginosa is a multidrug-resistant Gram-negative pathogen and one of the leading causes of ventilator-associated pneumonia and infections in patients with chronic obstructive pulmonary disease and cystic fibrosis. Murepavadin is a peptidomimetic that specifically targets outer-membrane lipopolysaccharide transport protein LptD of P. aeruginosa. In this study, we find that murepavadin enhances the bactericidal efficacy of ciprofloxacin. We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux. In addition, the murepavadin-ciprofloxacin combination exhibits a synergistic bactericidal effect in an acute murine pneumonia model. In conclusion, our results identify an effective drug combination for the treatment of P. aeruginosa infections.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Murepavadin.

01AnimalNot a test of Murepavadin aloneAnimal study (in vivo)Efficacy outcome
In acute murine pneumonia, murepavadin with ciprofloxacin exhibited a synergistic bactericidal effect.
In plain wordsIn mice with acute pneumonia, murepavadin with ciprofloxacin showed synergistic bacterial killing.
Peptide
Murepavadin
Outcome
IncreaseCombination bactericidal synergy
Study
Mousen: not reported in source
Acute murine pneumonia
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
In addition, the murepavadin-ciprofloxacin combination exhibits a synergistic bactericidal effect in an acute murine pneumonia model.
In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.
Show in the study text Report a problemFND-3933498504
02LabNot a test of Murepavadin aloneIn vitro (cells)Activity measurement
In vitro, murepavadin with ciprofloxacin enhanced bactericidal efficacy.
In plain wordsIn lab tests, murepavadin with ciprofloxacin increased bacterial killing.
Peptide
Murepavadin
Outcome
IncreaseCiprofloxacin bactericidal efficacy
Study
Pseudomonas aeruginosan: not reported in source
Pseudomonas aeruginosa cultures
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
In this study, we find that murepavadin enhances the bactericidal efficacy of ciprofloxacin.
In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.
Show in the study text Report a problemFND-3933498501
03LabNot a test of Murepavadin aloneIn vitro (cells)Mechanism
In bacteria, murepavadin with ciprofloxacin increased intracellular ciprofloxacin accumulation.
In plain wordsIn lab tests, murepavadin with ciprofloxacin increased antibiotic accumulation inside bacteria.
Peptide
Murepavadin
Outcome
IncreaseIntracellular ciprofloxacin accumulation
Study
Pseudomonas aeruginosan: not reported in source
Pseudomonas aeruginosa cultures
Outcome group
Receptor activity and mechanism · Infection
Source sentences
Summary
We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux.
In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.
Show in the study text Report a problemFND-3933498502
04LabNot a test of Murepavadin aloneIn vitro (cells)Mechanism
In bacteria, murepavadin suppressed drug efflux during ciprofloxacin exposure.
In plain wordsIn lab tests, murepavadin suppressed drug removal from bacteria during ciprofloxacin exposure.
Peptide
Murepavadin
Outcome
DecreaseDrug efflux
Study
Pseudomonas aeruginosan: not reported in source
Pseudomonas aeruginosa cultures
Outcome group
Receptor activity and mechanism · Infection
Source sentences
Summary
We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux.
In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.
Show in the study text Report a problemFND-3933498503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.